GlassScriptPhysician profile
Melissa A Albert
NPI 1033313911
$4,441.46
in general payments reported to CMS, 2019-2025
30 companies · $668 in 2025
The $668 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $321 · 2021: $393 · 2022: $763 · 2023: $797 · 2024: $900 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,364.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $963.23 | 2021-2025 | Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $401.10 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $390.54 | 2019-2025 | Aristada, Vivitrol, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $375.73 | 2022-2025 | Caplyta |
| Corium, LLC | $356.52 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $308.69 | 2020-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $190.05 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $182.93 | 2019-2025 | Trintellix |
| Allergan, INC. | $164.96 | 2019-2020 | |
| Tris Pharma INC | $146.61 | 2019-2021 | |
| Novo Nordisk INC | $132.77 | 2023-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $115.43 | 2019-2025 | Spravato, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $89.39 | 2021-2025 | Qelbree, Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.10 | 2019 | |
| Neos Therapeutics, LP | $77.21 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $56.82 | 2024-2025 | Fanapt |
| Almatica Pharma LLC | $49.82 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $41.79 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $38.45 | 2020 | |
| Hikma Pharmaceuticals USA | $36.33 | 2019-2023 | Mitigare, Ryaltris |
| Merck Sharp & Dohme LLC | $34.39 | 2019 | |
| Avanir Pharmaceuticals, INC. | $34.36 | 2019-2021 | |
| Lundbeck LLC | $32.08 | 2019-2024 | Rexulti |
| Shire North American Group INC | $27.33 | 2019 | |
| Exact Sciences Corporation | $26.15 | 2025 | Cologuard Collection Kit |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.42 | 2024 | |
| Axsome Therapeutics, INC. | $22.06 | 2023 | Auvelity |
| Sage Therapeutics, LLC | $17.45 | 2025 | Zurzuvae |
| Currax Pharmaceuticals LLC | $13.40 | 2021 | |
| Dexcom, INC. | $13.35 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.